Daiichi Sankyo Canada officially opened its new Canadian headquarters in Toronto,marking a major milestone in the company’s 125-year history and its growing NorthAmerican presence.
Since establishing operations in 2023, Daiichi Sankyo Canada hasexpanded to more than 30 employees—with plans to double in the coming years—while actively supporting 18 oncology clinical trials across 43 sites nationwide.
Through partnerships with leading institutions such as Princess Margaret Cancer Centre, now part of the Daiichi Sankyo Oncology Early Development Consortium, and global collaborators including AstraZeneca and Merck, the company is bringing its most innovative HER2-targeted and oncology therapies to Canadian patients.
The Japan Society is very proud to have a Sustaining Member like Daiichi Sankyo growing and establishing its presence across Canada, further strengthening the bridge between our two countries.
The grand opening underscored the strength of Canada–Japan business ties and the shared commitment to advancing life sciences. Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo, highlighted Canada’s world-class research ecosystem and deep talent pool as essential to the company’s ambition to become a global top 10 oncology company by 2030.
Remarks from Deputy Consul General Miho Matsui and Ontario’s Parliamentary Assistant to the Minister of Economic Development, Tyler Albrecht, emphasized Daiichi Sankyo’s investment as a vote of confidence in Ontario’s life sciences hub and a powerful example of how Japan–Canada collaboration can deliver
life-changing, sustainable healthcare innovations for patients in both nations and around the world.
Since 2023, the Japan Society has been hosting a round table for Japanese pharmaceutical companies in Canada. We thank Fatih, Sarah and Daiichi Sankyo’s support in the leadership in this group.
